Russell McMahen
Technik-/Wissenschafts-/F&E-Leiter bei AYTU BIOPHARMA, INC.
Profil
Russell Lee McMahen is currently the Senior Vice President-Research & Development at Aytu Biopharma, Inc. He previously worked as the Senior Vice President-Research & Development at Neos Therapeutics, Inc. from 2011 to 2021.
Prior to that, he was a Principal at IVAX Pharmaceuticals, Inc. He obtained his undergraduate degree from Louisiana Tech University.
Aktive Positionen von Russell McMahen
| Unternehmen | Position | Beginn |
|---|---|---|
| AYTU BIOPHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
Ehemalige bekannte Positionen von Russell McMahen
| Unternehmen | Position | Ende |
|---|---|---|
| NEOS THERAPEUTICS, INC. | Geschäftsführer | - |
IVAX Pharmaceuticals, Inc.
 IVAX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IVAX Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products, which are sold to wholesalers, retail drug chains, retail pharmacies, hospital groups, nursing home providers and government agencies in the United States. The company was founded in 1987 by Philip Frost and Michael Jaris. It is headquartered in Miami, FL. | Corporate Officer/Principal | - |
Ausbildung von Russell McMahen
| Louisiana Tech University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AYTU BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
IVAX Pharmaceuticals, Inc.
IVAX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IVAX Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products, which are sold to wholesalers, retail drug chains, retail pharmacies, hospital groups, nursing home providers and government agencies in the United States. The company was founded in 1987 by Philip Frost and Michael Jaris. It is headquartered in Miami, FL. | Health Technology |
